Paper21397538
Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
Koeberl DD and 8 others. Mol Genet Metab, 2011. Cited by 63 papers, by iCite.
Cite this record
ConductScience Library. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Papers, record 21397538. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21397538
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Enzyme Replacement Therapy | Major topic |
| Glycogen Storage Disease Type II | Major topic |
| Muscle, Skeletal | Major topic |
| Receptor, IGF Type 2 | Major topic |
| Adrenergic beta-Agonists | |
| Animals | |
| Clenbuterol | |
| Disease Models, Animal | |
| Glycogen | |
| Male | |
| Mice | |
| Mice, Knockout | |
| Motor Activity | |
| alpha-Glucosidases |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 HL081122 | NHLBI NIH HHS | United States | R01HL081122 | PubMed and NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01942590 | Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy | Background |
Source ClinicalTrials.gov
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10430861 | Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. | Proc Natl Acad Sci U S A | 1999 | https://conductscience.org/library/papers/10430861 | PubMed |
| 2 | 12507915 | Tissue-specific inactivation of murine M6P/IGF2R. | Am J Pathol | 2003 | https://conductscience.org/library/papers/12507915 | PubMed |
| 3 | 11808348 | [Adult form of acid maltase deficiency presenting with pattern of muscle weakness resembling facioscapulohumeral dystrophy]. | Rinsho Shinkeigaku | 2001 | https://conductscience.org/library/papers/11808348 | PubMed |
| 4 | 15585406 | Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. | Mol Ther | 2005 | https://conductscience.org/library/papers/15585406 | PubMed |
| 5 | 15190196 | Enzyme replacement and enhancement therapies for lysosomal diseases. | J Inherit Metab Dis | 2004 | https://conductscience.org/library/papers/15190196 | PubMed |
| 6 | 18391178 | Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. | Physiol Rev | 2008 | https://conductscience.org/library/papers/18391178 | PubMed |
| 7 | 15839836 | Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. | Biochem J | 2005 | https://conductscience.org/library/papers/15839836 | PubMed |
| 8 | 14567965 | Enzyme replacement therapy in the mouse model of Pompe disease. | Mol Genet Metab | 2003 | https://conductscience.org/library/papers/14567965 | PubMed |
| 9 | 17151143 | Extracellular signal-regulated kinase pathway is differentially involved in beta-agonist-induced hypertrophy in slow and fast muscles. | Am J Physiol Cell Physiol | 2007 | https://conductscience.org/library/papers/17151143 | PubMed |
| 10 | 11739080 | Role of IGF-I and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol. | Am J Physiol Endocrinol Metab | 2002 | https://conductscience.org/library/papers/11739080 | PubMed |
| 11 | 19277015 | Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. | Mol Ther | 2009 | https://conductscience.org/library/papers/19277015 | PubMed |
| 12 | 19649685 | Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. | J Neurol | 2010 | https://conductscience.org/library/papers/19649685 | PubMed |
| 13 | 16432501 | Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. | Br J Pharmacol | 2006 | https://conductscience.org/library/papers/16432501 | PubMed |
| 14 | 9844629 | A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. | Mol Cell | 1998 | https://conductscience.org/library/papers/9844629 | PubMed |
| 15 | 15585405 | Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. | Mol Ther | 2005 | https://conductscience.org/library/papers/15585405 | PubMed |
| 16 | 9668092 | Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. | J Biol Chem | 1998 | https://conductscience.org/library/papers/9668092 | PubMed |
| 17 | 2481447 | Effects of clenbuterol and propranolol on muscle mass. Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy. | Biochem J | 1989 | https://conductscience.org/library/papers/2481447 | PubMed |
| 18 | 20817528 | Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. | Neuromuscul Disord | 2010 | https://conductscience.org/library/papers/20817528 | PubMed |
| 19 | 17093970 | Molecular impact of clenbuterol and isometric strength training on rat EDL muscles. | Pflugers Arch | 2007 | https://conductscience.org/library/papers/17093970 | PubMed |
| 20 | 14677650 | Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses. | J Muscle Res Cell Motil | 2003 | https://conductscience.org/library/papers/14677650 | PubMed |
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 63 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41199666 | Effects of hypoxia and hyperoxia on exercise-induced metabolomic and transcriptomic profiles in equine skeletal muscle. | J Exp Biol | 2025 | https://conductscience.org/library/papers/41199666 | PubMed |
| 38948331 | Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells. | Mol Ther Nucleic Acids | 2024 | https://conductscience.org/library/papers/38948331 | PubMed |
| 38232139 | Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders. | Sci Transl Med | 2024 | https://conductscience.org/library/papers/38232139 | PubMed |
| 37686045 | Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37686045 | PubMed |
| 37463048 | AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice. | JCI Insight | 2023 | https://conductscience.org/library/papers/37463048 | PubMed |
| 36911201 | A universal GlycoDesign for lysosomal replacement enzymes to improve circulation time and biodistribution. | Front Bioeng Biotechnol | 2023 | https://conductscience.org/library/papers/36911201 | PubMed |
| 36805083 | Phase I study of liver depot gene therapy in late-onset Pompe disease. | Mol Ther | 2023 | https://conductscience.org/library/papers/36805083 | PubMed |
| 36138713 | The Clinical Management of Pompe Disease: A Pediatric Perspective. | Children (Basel) | 2022 | https://conductscience.org/library/papers/36138713 | PubMed |
| 35682977 | Isogenic GAA-KO Murine Muscle Cell Lines Mimicking Severe Pompe Mutations as Preclinical Models for the Screening of Potential Gene Therapy Strategies. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35682977 | PubMed |
| 35411297 | To detect potential pathways and target genes in infantile Pompe patients using computational analysis. | Bioimpacts | 2022 | https://conductscience.org/library/papers/35411297 | PubMed |
| 35081735 | Efficacious Androgen Hormone Administration in Combination with Adeno-Associated Virus Vector-Mediated Gene Therapy in Female Mice with Pompe Disease. | Hum Gene Ther | 2022 | https://conductscience.org/library/papers/35081735 | PubMed |
| 34606154 | Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease. | EMBO Mol Med | 2021 | https://conductscience.org/library/papers/34606154 | PubMed |
| 34565280 | Carnitine is a pharmacological allosteric chaperone of the human lysosomal α-glucosidase. | J Enzyme Inhib Med Chem | 2021 | https://conductscience.org/library/papers/34565280 | PubMed |
| 34400331 | Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies. | Mol Ther | 2021 | https://conductscience.org/library/papers/34400331 | PubMed |
| 33953320 | Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease. | Commun Biol | 2021 | https://conductscience.org/library/papers/33953320 | PubMed |
| 33304924 | CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges. | Front Mol Biosci | 2020 | https://conductscience.org/library/papers/33304924 | PubMed |
| 32962155 | Pompe Disease: New Developments in an Old Lysosomal Storage Disorder. | Biomolecules | 2020 | https://conductscience.org/library/papers/32962155 | PubMed |
| 31796685 | Advancements in AAV-mediated Gene Therapy for Pompe Disease. | J Neuromuscul Dis | 2020 | https://conductscience.org/library/papers/31796685 | PubMed |
| 31645300 | Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease. | Mol Genet Metab | 2020 | https://conductscience.org/library/papers/31645300 | PubMed |
| 31419653 | Engineered skeletal muscles for disease modeling and drug discovery. | Biomaterials | 2019 | https://conductscience.org/library/papers/31419653 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GAA | 2548 | PubTator's text mining | https://conductscience.org/library/genes/2548 | NCBI Gene |
| IGF2R | 3482 | PubTator's text mining | https://conductscience.org/library/genes/3482 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21397538
GET https://conductscience.org/api/papers/v1/21397538/references?page=2